...ALK inhibitor, for NSCLC and have the compound in Phase II testing for solid tumors. Xcovery Holding Co. LLC...

...at Shire plc, which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired in January. Cancer company Xcovery Holding Co. LLC...
...Liang. Mao was VP and head of the Johnson & Johnson China Lung Cancer Center. Xcovery...
...Staff Acadia Pharmaceuticals Inc. Aerie Pharmaceuticals Inc. Artios Pharma Ltd. Audentes Therapeutics Inc. Global Health Innovative Technology (GHIT) Fund Surface Oncology Inc. Xcovery Holding Co. LLC American...

...III compounds. Ensartinib (X-396), a candidate for NSCLC, was obtained in a 2014 deal with Xcovery Holding Co. LLC...
...Jihe Group Co. Ltd., Hangzhou, China Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tyrogenex Inc., Rockville, Md. Xcovery Holding Co. LLC...

...the Genentech Inc. unit of Roche market Alecensa alectinib, an ALK inhibitor, to treat NSCLC. Xcovery Holding Co. LLC...

...AstraZeneca plc (LSE:AZN; NYSE:AZN); ensartinib (X-396), an inhibitor of anaplastic lymphoma kinase (ALK) , from Xcovery Holding Co. LLC...
...safety, pharmacokinetics and progression-free survival (PFS) Status: Phase II started Milestone: NA Chris Lieu ensartinib larotrectinib Lynparza selumetinib tazemetostat X-396 Zelboraf Epizyme Inc. Loxo Oncology Inc. Xcovery Holding Co. LLC Array...

...kinase kinase 1 ( MAP2K1 ; MEK1) and MAP2K2 (MEK2); ensartinib ( X-396 ) from Xcovery Holding Co. LLC...
...screen 1,000 patients; each treatment arm will enroll at least 20 patients. Chris Lieu ensartinib larotrectinib Lynparza selumetinib tazemetostat X-396 Zelboraf Epizyme Inc. Loxo Oncology Inc. Xcovery Holding Co. LLC Array...

...and Co. (NYSE:LLY), Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Loxo Oncology Inc . (NASDAQ:LOXO) and Xcovery Holding Co. LLC...

...of Roche (SIX:ROG; OTCQX:RHHBY), Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Loxo Oncology Inc. (NASDAQ:LOXO), and Xcovery Holding Co. LLC...

...prior chemotherapy regimen and no prior ALK inhibitor. Betta has Chinese rights to X-396 from Xcovery...
...a 2014 deal (see BioCentury, Nov. 3, 2014). Betta Pharmaceuticals Co. Ltd. , Hangzhou, China Xcovery Holding Co. LLC...

...is resigning. Michael Webb will replace Sheridan Snyder as president and CEO of cancer play Xcovery Holding Co. LLC...
...Tyrogenex Inc. (West Palm Beach, Fla.). Snyder, who co-founded both companies, will remain chairman at Xcovery...